Allergan PLC, which last year agreed to merge with Pfizer Inc., on Thursday said it will buy clinical-stage pharmaceutical company Anterios Inc.
Under the terms of the deal, Allergan will pay Anterios $90 million up front, plus milestone payments.
Anterios is the developer of NDS, a technology that delivers neurotoxins through the skin instead of through injection. Allergan is perhaps best known as the maker of Botox, a neurotoxin with both cosmetic and therapeutic variations used to treat everything from wrinkles to osteoarthritis.
In a news release, Allergan Executive Vice President David Nicholson said the deal allows Allergan to advance “a new delivery system and formulations that are appealing to both patients and physicians.”
Allergan also will get global rights to ANT-1207, a topical drug being investigated for the use of excessive sweating, acne and crow’s feet.
Allergan in November agreed to a more than $150 billion tie-up with Pfizer, a historic merger that would create the world’s biggest drugmaker. The combined company will have top-selling products including Pfizer’s Prevnar pneumonia vaccine and Allergan’s Botox, and an industry-topping R&D budget.
By Chelsey Dulaney
Source: Wall Street Journal
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
